NCT Number: NCT00189800
A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder
The purpose of this study is to ascertain the clinical results of solifenacin succinate of PIII study conducted in the original country using Korean patients with an overactive bladder.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Anyang, South Korea
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Symptoms of overactive bladder
- Must be able to complete the micturition diary
Exclusion criteria
- Pregnant or lactating
- Clinically significant outflow obstruction
- Significant post void residual urine
- Significant stress incontinence
- Urinary tract infection
- Chronic inflammation
- Bladder stones
- Previous pelvic radiation therapy
- Previous or current malignant disease of the pelvic organs
- Uncontrolled narrow angle glaucoma
- Urinary or gastric retention
- Electrostimulation therapy
- Bladder training
- Diabetic neuropathy
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Astellas Pharma Inc
Industry
Collaborators
- Astellas Pharma Korea, Inc.
Registry information
Important dates
- First posted
- Sep 19, 2005
- Registry last updated
- Nov 17, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead
NCT05799313
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Cleveland, Ohio, United States
View Trial DetailsUrinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks
NCT05557279
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Maywood, Illinois, United States
View Trial DetailsrTMS in Overactive Bladder
NCT06198439
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Houston, Texas, United States
View Trial DetailsEffect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder
NCT06206512
Cardiovascular Diseases, Female Urogenital Diseases
Dallas, Texas, United States
View Trial Details